We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IBG:NASDAQInnovation Beverage Group Limited Analysis

Data as of 2026-06-03 - not real-time

$1.09

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Innovation Beverage Group trades around $1.09, which sits just above its 20‑day SMA (0.87) but remains dramatically below the 200‑day SMA (7.87), signaling a long‑term bearish backdrop despite a modest short‑term uplift. The RSI at 57 shows neutral momentum, while the MACD histogram is positive, hinting at a fleeting bullish signal that is unlikely to overcome the prevailing downtrend. With support near $0.72 and resistance at $1.10, the stock is perched at a technical ceiling amid extreme 30‑day volatility of 95% and a beta of 0.63, while its historical max drawdown of nearly –98% underscores the peril of large price swings.
Fundamentally, the company is in distress: revenue is stagnant, operating margins are –121% and net profit margin –88%, and cash flow is deeply negative. Debt ($719k) dwarfs cash ($188k) leading to a debt‑to‑equity ratio of 27, and the price‑to‑book ratio of 0.18 reflects a market‑price far below book value but not enough to offset the solvency concerns. The firm has received a Nasdaq delisting warning for late filing, elevating regulatory risk, and it offers no dividend, making the outlook financially precarious.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 9/10

Key Factors

  • Technical bearish bias with price near resistance
  • Nasdaq delisting warning increasing regulatory pressure
  • Severe cash‑flow deficits and high debt load

Medium Term

1–3 years
Cautious
Model confidence: 8/10

Key Factors

  • Continued operating losses and negative EBITDA
  • Elevated volatility and thin trading volume
  • Unresolved compliance issues jeopardizing listing status

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside from deep discount to book value
  • Possibility of restructuring or capital infusion
  • Persistent uncertainty around profitability and regulatory standing

Key Metrics & Analysis

Financial Health

Profit Margin-87.72%
ROE-159.34%
ROA-32.68%
Debt/Equity26.87
P/B Ratio0.2
Op. Cash Flow$-1575298
Free Cash Flow$-1018082

Technical Analysis

TrendBearish
RSI57.2
Support$0.72
Resistance$1.10
MA 20$0.87
MA 50$1.02
MA 200$7.87
MACDBullish
VolumeStable
Fear & Greed Index92.75

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta0.63
Volatility95.61%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.